Key Takeaways:
InfuSystem Holdings, Inc. (NYSE American: INFU) announced a new stock repurchase program, authorizing the company to buy back up to $20 million of its common stock from July 1, 2026, through June 30, 2028.
"This authorization carries on the Company’s established buyback policy which we have used when appropriate to enhance shareholder value," said Carrie Lachance, Chief Executive Officer of InfuSystem. "I believe the stock repurchase program demonstrates our confidence in being able to continue to execute with discipline, deliver profitable growth and drive long term value for the rest of 2026 and beyond."
The new program will replace the previous authorization, which is set to expire on June 30, 2026. Under the current plan, InfuSystem repurchased approximately 1.6 million shares for about $11.9 million through March 31, 2026.
The buyback plan signals management's belief that the stock may be undervalued and provides a method to return capital to shareholders, potentially increasing earnings per share. Lachance noted that while strategic investments remain the top priority, the program offers "the flexibility to be opportunistic in repurchasing shares when valuations become attractive."
InfuSystem operates a two-platform model focused on outpatient care. The Patient Services platform provides clinic-to-home healthcare solutions involving durable medical equipment for Oncology, Pain Management, and Wound Therapy. The Device Solutions platform supports these services through direct payer rentals, sales of pumps and consumables, and biomedical services.
The new buyback authorization suggests that management is confident in its ability to generate sufficient cash flow from these operations to fund both strategic growth initiatives and shareholder returns. The repurchases can be made on the open market or through private transactions.
This article is for informational purposes only and does not constitute investment advice.
